GILD — Gilead Sciences, Inc.

Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Product Sales: $6.9 billion, up 5% year-over-year; $6.8 billion excluding Veklury, up 8%.
• HIV Sales: $5.0 billion, up 10% year-over-year. Biktarvy sales were $3.4 billion, up 7%.
• Trodelvy Sales: $402 million, up 37% year-over-year.
• Libdelzi Sales: $133 million, more than tripled year-over-year.
• Non-GAAP Diluted EPS: $2.03, up 12% year-over-year.
• Operating Margin: 47%.
• R&D Expenses: $1.4 billion, flat year-over-year.
• SG&A Expenses: Up 12% year-over-year, primarily due to Yes2Go launch costs.

2. Strategic Updates and Business Highlights

• HIV Business Growth: Strong performance driven by Biktarvy and a significant 87% growth in the U.S. PrEP market, particularly from the launch of Yes2Go.
• Oncology Pipeline: Trodelvy's sales growth and expected regulatory decisions for first-line metastatic breast cancer. The acquisition of Tubulis is anticipated to enhance Gilead's oncology portfolio.
• Acquisitions: Completed acquisition of Arcellx and pending acquisitions of Oral Medicines and Tubulis, aimed at expanding Gilead's capabilities in oncology and inflammation.
• Pipeline Expansion: 47 clinical programs in development, with multiple upcoming regulatory decisions and product launches expected.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Increased by $400 million, now expecting total product sales between $30.0 billion and $30.4 billion.
• HIV Sales Growth: Revised to approximately 8% year-over-year, up from 6%.
• Yes2Go Sales Guidance: Increased to $1 billion for 2026, reflecting strong early performance.
• Operating Income: Expected to be between $2.4 billion and $2.9 billion for 2026, with a focus on maintaining strong margins.

4. Bad News, Challenges, or Points of Concern

• Seasonality Impact: Sequential sales down 12% due to typical first-quarter seasonality.
• HCV and Cell Therapy Sales Decline: Notable declines in HCV and cell therapy sales, reflecting competitive pressures.
• Policy-Related Headwinds: Approximately 2% growth headwind from drug pricing agreements and changes to the Affordable Care Act.
• Market Competition: Potential competitive pressures from new entrants in oncology, particularly with Trodelvy facing competition from Astra and Daiichi’s datopotamab.

5. Notable Q&A Insights

• Yes2Go Launch: Strong uptake in urban areas with high HIV prevalence; ongoing efforts to increase awareness in rural regions.
• Biclen Opportunity: Positioned to simplify treatment for patients on complex regimens, with a focus on capturing switch market share.
• Anitocel Launch Dynamics: Anticipated strong enthusiasm from KOLs and treatment centers, with a substantial market opportunity in fourth-line CAR T therapy.
• Tubulis Acquisition: Highlighted for its potential in ovarian cancer and broader applications in oncology, with a focus on unique platform technologies.
• Adherence and Persistency: Early data suggests positive trends in adherence for Yes2Go, with ongoing monitoring and marketing efforts to support patient retention.

Overall, Gilead Sciences reported a strong quarter with significant growth in key therapeutic areas, strategic acquisitions to bolster its pipeline, and an optimistic outlook for the remainder of 2026, despite facing some competitive and regulatory challenges.